



19 APR 2006

UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

KNOBBE MARTENS OLSON & BEAR LLP
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE CA 92614

In re Application of
OLSSON

Application No.: 10/568,149

DECISION ON

PCT No.: PCT/US04/04765

PETITION UNDER

Int. Filing Date: 18 February 2004

37 CFR 1.137(b)

Priority Date: 19 February 2003

Attorney Docket No.: ACADIA.033NP

For: 2-AMINOETHYL SUBSTITUTED
PYRIMIDIN-2-ONES CYCLOPROPANES
PYRAZOLINES PYRIMIDINES AND
BENZOTHIAZEPINES AND THEIR USES AS
UROTENSIN II AND SOMATOSTATIN 5
RECEPTOR LIGANDS

This decision is in response to applicants' submission filed 10 February 2006.

BACKGROUND

On 18 February 2004, applicants filed international application PCT/US04/04765 which designated the U.S. and claimed a priority date of 19 February 2003. A copy of the international application was communicated to the United States Patent and Trademark Office (USPTO) from the International Bureau on 02 September 2004. The thirty-month period for paying the basic national fee in the United States expired at midnight on 19 August 2005.

On 10 February 2006, applicants filed a transmittal letter for entry into the national stage in the United States, which was accompanied by, *inter alia*, the basic national fee and a petition under 37 CFR 1.137(b) to revive the application.

DISCUSSION

A petition to revive the present application under 37 CFR 1.137(b) must include:

- (1) The required reply;
- (2) The petition fee;
- (3) A statement that the entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition was unintentional.

As to item (1), applicant submitted the basic national fee on 10 February 2006.

As to item (2), applicant submitted the petition fee on 10 February 2006.

As to item (3), the required statement has been provided.

A review of the application file reveals that, with the filing of the present petition and accompanying papers, a proper response has been submitted and all of the requirements of 37 CFR 1.137(b) for revival have been satisfied and revival is therefore appropriate.

CONCLUSION

The petition under 37 CFR 1.137(b) is **GRANTED** for the reasons set forth above.

Please direct further correspondence with respect to this matter to Mail Stop PCT, Commissioner for Patents, Office of PCT Legal Administration, P.O. Box 1450, Alexandria, Virginia 22313-1450, with the contents of the letter marked to the attention of the Office of PCT Legal Administration.

This application is being forwarded to the National Stage Processing Branch of the Office of PCT Operations to continue national stage processing of the application including preparing and mailing a NOTIFICATION OF MISSING REQUIREMENTS (Form PCT/DO/EO/905) requiring an oath or declaration in compliance with 37 CFR 1.497(a)-(b) and the surcharge under 37 CFR 1.492(e) for providing the oath or declaration later than thirty months from the priority date.



Daniel Stemmer
Legal Examiner
PCT Legal Affairs
Office of Patent Cooperation Treaty
Legal Administration
Telephone: (571) 272-3301
Facsimile: (571) 273-0459